Cargando…

Detection and clearance in Alzheimer’s disease: leading with illusive chemical, structural and morphological features of the targets

Detalles Bibliográficos
Autor principal:	Gales, Luís
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10581563/ https://www.ncbi.nlm.nih.gov/pubmed/37721271 http://dx.doi.org/10.4103/1673-5374.380897

Ejemplares similares

The Sun/Moon Illusion in a Medieval Irish Astronomical Tract
por: Ross, Helen E.
Publicado: (2019)

The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology
por: Apostolova, Liana G., et al.
Publicado: (2021)

How mind-body therapies might reduce pathological features of Alzheimer’s disease
por: Hüttenrauch, Melanie, et al.
Publicado: (2022)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

Targeting the guanine-based purinergic system in Alzheimer's disease
por: Lanznaster, Débora, et al.
Publicado: (2017)

Dual targeting nano-approaches for Alzheimer's disease etiology
por: Hettiarachchi, Sajini D., et al.
Publicado: (2020)

Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease
por: Sumbria, Rachita K.
Publicado: (2020)

Targeting immunometabolic pathways for combination therapy in Alzheimer's disease
por: Erichsen, Jennifer, et al.
Publicado: (2023)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

Lingo-1: a novel target in therapy for Alzheimer's disease?
por: Fernandez-Enright, Francesca, et al.
Publicado: (2016)

Aβ Clearance, “hub” of Multiple Deficiencies Leading to Alzheimer Disease
por: Gallina, Pasquale, et al.
Publicado: (2015)

Does Local Coherence Lead to Targeted Regressions and Illusions of Grammaticality?
por: Paape, Dario, et al.
Publicado: (2021)

Caveolae, CD109, and endothelial cells as targets for treating Alzheimer's disease
por: Fessel, Jeffrey
Publicado: (2020)

Neurovascular ageing: transcriptomic readout and implications on therapeutic targeting in Alzheimer's disease
por: Li, Zhongqi, et al.
Publicado: (2021)

CD34(+) progenitor cells as diagnostic and therapeutic targets in Alzheimer’s disease
por: Romaus-Sanjurjo, Daniel, et al.
Publicado: (2022)

Is EAAT2 a potential therapeutic intervention target for Alzheimer’s disease?
por: Wood, Oliver WG, et al.
Publicado: (2023)

Targeting calcium signaling in Alzheimer’s disease: challenges and promising therapeutic avenues
por: Song, LinLin, et al.
Publicado: (2023)

The seeming paradox of adenosine receptors as targets for the treatment of Alzheimer's disease: agonists or antagonists?
por: Marzagalli, Rubina, et al.
Publicado: (2015)

APOE targeting strategy in Alzheimer’s disease: lessons learned from protective variants
por: Bu, Guojun
Publicado: (2022)

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target
por: Govindpani, Karan, et al.
Publicado: (2019)

Retinal Examination Modalities in the Early Detection of Alzheimer's Disease: Seeing Brain Through the Eye
por: Ma, Xiaoxi, et al.
Publicado: (2022)

Preventative medicine and Alzheimer’s disease: is Alzheimer’s disease risk reduction achievable?
por: Sinyor, Benjamin, et al.
Publicado: (2021)

Is it time to rethink the Alzheimer's disease drug development strategy by targeting its silent phase?
por: Souchet, Benoit, et al.
Publicado: (2018)

Acid-sensing ion channel 1a: a novel target in Alzheimer’s disease?
por: Mango, Dalila, et al.
Publicado: (2022)

Emerging small-molecule therapeutic approaches for Alzheimer's disease and Parkinson's disease based on targeting microRNAs
por: Abdelrahman, Somaya A., et al.
Publicado: (2021)

Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
por: Taylor, Ronald P., et al.
Publicado: (2020)

Recent advancements toward non-invasive imaging of retinal amyloid-beta for early detection of Alzheimer’s disease
por: Wang, Liang, et al.
Publicado: (2022)

Endocannabinoid metabolism and Alzheimer's disease
por: Chen, Chu
Publicado: (2022)

OxInflammation in Alzheimer’s disease
por: Cervellati, Carlo, et al.
Publicado: (2023)

Historic recurrences in medicinal chemistry: nature-inspired structures as a new opportunity for novel multi-target anti-Alzheimer’s drugs
por: Piemontese, Luca
Publicado: (2023)

C. elegans RAB-35: Dual roles in apoptotic cell clearance
por: Rocheleau, Christian E.
Publicado: (2018)

Choroidal Proteins Involved in Cerebrospinal Fluid Production may be Potential Drug Targets for Alzheimer’s Disease Therapy
por: Wostyn, Peter, et al.
Publicado: (2011)

Tetrahydrohyperforin (IDN5706) targets the endoplasmic reticulum for autophagy activation: potential mechanism for Alzheimer's disease therapy
por: González, Alexis, et al.
Publicado: (2016)

The Role of Feature Tracking in the Furrow Illusion
por: Allard, Rémy, et al.
Publicado: (2016)

New unexpected role for Wolfram Syndrome protein WFS1: a novel therapeutic target for Alzheimer’s disease?
por: Chen, Shuo, et al.
Publicado: (2022)

Find-me and eat-me signals in apoptotic cell clearance: progress and conundrums
por: Ravichandran, Kodi S.
Publicado: (2010)

Next generation therapeutics for Alzheimer's disease
por: Bredesen, Dale E, et al.
Publicado: (2013)

New Approaches to Treating Alzheimer’s Disease
por: Zheng, Hailin, et al.
Publicado: (2015)

Advancing combination therapy for Alzheimer's disease
por: Salloway, Stephen P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_nh2juhgl722v85p6ntgarqdaf8